$7.000
+0.077 (+1.10%)收盤時
APM 資訊
APM 事件
Aptorum Group Ltd Trading Halted, News Pending
Aptorum Group Ltd trading halted, news pending
Aptorum's Merger with DiamiR Expected to Close on July 20, 2026
Aptorum Group announced that the closing of its merger with DiamiR Biosciences is anticipated to take place on or about July 20, 2026. In connection with the Merger, Aptorum intends to effect a share consolidation of its issued and outstanding class A and class B ordinary shares at a ratio of 1-to-10. The Reverse Split was approved by Aptorum's shareholders on June 9, 2026, at which time the shareholders also approved various transactions required to take place in connection with the anticipated closing of the Merger. In connection with the Merger, Aptorum shall redomicile as a Delaware company, under the name Niki BioSolutions. It is expected that as of the market open on July 20, 2026, the Company will trade shares of common stock on The Nasdaq Capital Market, under the new name Niki BioSolutions, new trading symbol "NIKI," and new CUSIP number 653942 102, on a split-adjusted basis.
Aptorum Group Collaborates with DiamiR on Alzheimer's Biomarkers
Aptorum Group and DiamiR Biosciences announced a collaboration between DiamiR and AlzLabs Precision Diagnostics to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.
Aptorum Group Receives Nasdaq Non-Compliance Notification
Aptorum Group announced that it has received a notification from Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550. The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group has been granted a 180-calendar-day grace period, until September 1 to regain compliance with the noted listing requirement. During this period, Aptorum Group intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.
Aptorum Group Collaborates with DiamiR to Validate APOE Testing Platform
Aptorum Group, DiamiR Biosciences, and Instant NanoBiosensors announced a collaboration between DiamiR and INB to validate INB's automated APOE testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Tony Chung, Chairman of Instant NanoBiosensors, stated, "We view DiamiR Biosciences as a highly respected reference laboratory. We believe that completing this validation and implementing the service together will strengthen confidence in the INB platform, expand DiamiR's validated service offerings, and establish a strong foundation for future collaboration and additional applications beyond APOE testing."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。